Date |
Title |
Dec 19, 2022 |
Illumina To Webcast Upcoming Investor Conference |
Dec 14, 2022 |
Illumina Ranks Among Top Scores on Dow Jones Sustainability Index and CDP |
Nov 15, 2022 |
Illumina To Webcast Upcoming Investor Conferences |
Nov 8, 2022 |
Illumina Boosts Genomics Innovation in the Emirates Through New State-of-the-Art Solutions Center |
Nov 3, 2022 |
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022 |
Nov 1, 2022 |
Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States |
Oct 18, 2022 |
Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis |
Oct 17, 2022 |
Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022 |
Oct 11, 2022 |
Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery |
Oct 6, 2022 |
Illumina to Announce Third Quarter 2022 Financial Results on Thursday, November 3, 2022 |
Sep 29, 2022 |
Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum |
Sep 29, 2022 |
Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health |
Sep 26, 2022 |
Illumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream |
Sep 19, 2022 |
Illumina to Host Upcoming Investor Day |
Sep 19, 2022 |
Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care |
Sep 14, 2022 |
Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications |
Sep 12, 2022 |
Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure |
Sep 8, 2022 |
Illumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call |
Sep 7, 2022 |
Illumina Genomics Forum to Feature Diverse Lineup of Visionary Global Leaders |
Sep 6, 2022 |
Illumina Intends to Appeal European Commission's Decision in GRAIL Deal |
Sep 5, 2022 |
Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients |
Sep 1, 2022 |
Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal |
Aug 30, 2022 |
Illumina Deepens Commitment to Customers in China with New Manufacturing Site |
Aug 29, 2022 |
Illumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight |
Aug 22, 2022 |
Illumina Genomics Forum to Feature 23andMe Co-founder and CEO Anne Wojcicki |
Aug 16, 2022 |
Minderoo Foundation and Illumina Commit $40M AUD to Apply Advanced Genomics to Marine Conservation |
Aug 15, 2022 |
Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics |
Aug 11, 2022 |
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022 |
Aug 8, 2022 |
Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics |
Jul 27, 2022 |
Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities |
Jul 18, 2022 |
Illumina Announces Inaugural Illumina Genomics Forum with a Conversation with Former U.S. President Barack Obama |
Jul 14, 2022 |
Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022 |
Jul 14, 2022 |
Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target |
Jun 28, 2022 |
Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health |
Jun 22, 2022 |
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome |
Jun 9, 2022 |
Joydeep Goswami Appointed Interim CFO; Sam Samad To Depart Illumina |
Jun 7, 2022 |
Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions |
Jun 2, 2022 |
Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO |
May 24, 2022 |
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy |
May 18, 2022 |
Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care |
May 5, 2022 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2022 |
May 5, 2022 |
Illumina and Deerfield Management partner to accelerate drug development |
Apr 28, 2022 |
Illumina To Webcast Upcoming Investor Conference |
Apr 25, 2022 |
Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children |
Apr 14, 2022 |
Illumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022 |
Apr 12, 2022 |
Illumina Expands Access to Genomics in Latin America through New State-of-the-Art Solution Center |
Apr 11, 2022 |
John Frank Joins Illumina as Chief Public Affairs Officer |
Apr 7, 2022 |
Illumina Releases Annual Corporate Social Responsibility Report |
Mar 16, 2022 |
Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications |
Mar 15, 2022 |
Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe |
Mar 14, 2022 |
Illumina Welcomes Carissa Rollins as Chief Information Officer |
Feb 21, 2022 |
Illumina To Webcast Upcoming Investor Conference |
Feb 10, 2022 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2021 |
Feb 3, 2022 |
Illumina To Webcast Upcoming Investor Conferences |
Feb 3, 2022 |
Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer |
Jan 24, 2022 |
Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia |
Jan 20, 2022 |
Illumina to Announce Fourth Quarter & Full Year 2021 Financial Results on Thursday, February 10, 2022 |
Jan 10, 2022 |
Illumina collaborates with Nashville Biosciences to accelerate medicines development |
Jan 10, 2022 |
Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care |
Jan 10, 2022 |
Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership |
Jan 10, 2022 |
Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference |
Jan 5, 2022 |
Illumina Enters Co-Development Partnership with SomaLogic |